Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

PDMR Transaction

25 Mar 2021 09:14

RNS Number : 4793T
IXICO plc
25 March 2021
Β 

25 March 2021

Β 

IXICO plc

("IXICO" or the "Company")

Β 

Director/PDMR Dealing

Β 

Β 

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that Mark Warne, Non-Executive Director, today purchased 14,250 ordinary shares in the Company at an average price of 63 pence.

Β 

Β 

For further information please contact:

Β 

IXICO plc +44 20 3763 7499

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

Β 

Cenkos Securities plc (Nominated adviser and sole broker) +44 20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

Michael F Johnson / Russell Kerr (Sales)

Β 

Walbrook PR Ltd

+44 (0)20 7933 8780

Β 

Paul McManus / Lianne Cawthorne /

IXICO@walbrookpr.com

Alice Woodings

Β 

The below makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Mark Warne

2

Reason for notification

On market purchase

a.

Position/Status

Non-Executive Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

IXICO plc

b.

LEI

2138005M1F59O6HWSA97

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of 1p each

ISIN: GB00BCLY7L40

Β 

b.

Nature of the transaction

Β Purchase of ordinary shares

c.

Price(s) and volume(s)

Price(s) per share

Volume(s)

Β£0.66

250 shares

Β£0.64

1500 shares

Β£0.65

1500 shares

Β£0.63

1500 shares

Β£0.61

1500 shares

Β£0.61

1500 shares

Β£0.63

1500 shares

Β£0.62

5000 shares

Β 

Β 

d.

Aggregated information

- Aggregated Volume

- Price

Β 

14,250 shares

Β£0.63

e.

Date of the transaction

24 March 2021

f.

Place of the transaction

London Stock Exchange, AIM Market

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHKELBLFXLBBBK
Date   Source Headline
20th Aug 20195:38 pmRNSDirector/PDMR Shareholding
19th Aug 20194:40 pmRNSSecond Price Monitoring Extn
19th Aug 20194:35 pmRNSPrice Monitoring Extension
19th Aug 20197:00 amRNSTrading Update
9th Aug 20197:00 amRNSIXICO provides update on new & current contracts
23rd Jul 201911:05 amRNSSecond Price Monitoring Extn
23rd Jul 201911:00 amRNSPrice Monitoring Extension
11th Jul 20197:00 amRNSDirector and PDMR share purchase
10th Jun 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHalf Yearly Report to 31 March 2019
10th May 20197:00 amRNSNotice of Results
25th Apr 20197:00 amRNSUpdate for first half of year ending 31 March 2019
24th Apr 20197:00 amRNSAnnounces two new biopharmaceutical contracts
12th Apr 20197:00 amRNSChange of Adviser
19th Mar 20194:20 pmRNSHolding(s) in Company
18th Mar 201912:24 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSDirector/PDMR Shareholding
5th Mar 20197:00 amRNSLate phase clinical study in Huntington's disease
1st Mar 20197:00 amRNSIXICO chosen for new Medical Imaging & AI Centre
7th Feb 20197:00 amRNSAppointment of Chief Financial Officer
11th Dec 20187:00 amRNSDirectorate Change
4th Dec 20187:00 amRNSFinal Results
4th Dec 20187:00 amRNSScope expanded with top 10 biopharma company
15th Oct 20187:00 amRNSPre-Close Trading Update
21st Sep 20184:46 pmRNSResult of General Meeting - Amended
21st Sep 201811:00 amRNSResult of General Meeting
11th Sep 20187:00 amRNSContract with top 10 global pharmaceutical company
3rd Sep 20187:00 amRNSProposed Capital Reorganisation
30th Aug 20187:00 amRNSContract expansion with biopharmaceutical company
21st Aug 20187:00 amRNSTrading Statement
13th Aug 20187:00 amRNSAgreement
13th Jun 20189:00 amRNSImplementation of Long Term Incentive Plan
12th Jun 20187:00 amRNSNotification of the cessation of a clinical trial
7th Jun 20189:47 amRNSIssue of Equity
31st May 20183:32 pmRNSHolding(s) in Company
31st May 20183:30 pmRNSHolding(s) in Company
30th May 201811:48 amRNSHolding(s) in Company
30th May 201811:45 amRNSHolding(s) in Company
30th May 20189:32 amRNSDirector/PDMR Shareholding
29th May 201812:08 pmRNSResult of General Meeting
23rd May 20183:29 pmRNSDirector/PDMR Shareholding
23rd May 20187:00 amRNSHalf-year Report
14th May 20187:00 amRNSNew contract with top 10 pharmaceutical company
10th May 20187:00 amRNSExpansion of two biopharmaceutical contracts
3rd May 20187:00 amRNSNotice of Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.